Logo image of LFCR

LIFECORE BIOMEDICAL INC (LFCR) Stock Fundamental Analysis

NASDAQ:LFCR - Nasdaq - US5147661046 - Common Stock - Currency: USD

5.94  +0.22 (+3.85%)

After market: 5.94 0 (0%)

Fundamental Rating

2

Overall LFCR gets a fundamental rating of 2 out of 10. We evaluated LFCR against 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of LFCR have multiple concerns. LFCR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year LFCR has reported negative net income.
LFCR had a positive operating cash flow in the past year.
LFCR had negative earnings in 4 of the past 5 years.
LFCR had negative operating cash flow in 4 of the past 5 years.
LFCR Yearly Net Income VS EBIT VS OCF VS FCFLFCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

With a decent Return On Assets value of -6.42%, LFCR is doing good in the industry, outperforming 63.16% of the companies in the same industry.
Looking at the Return On Equity, with a value of -27.42%, LFCR is in line with its industry, outperforming 43.86% of the companies in the same industry.
Industry RankSector Rank
ROA -6.42%
ROE -27.42%
ROIC N/A
ROA(3y)-25.28%
ROA(5y)-17.88%
ROE(3y)-129.31%
ROE(5y)-84.12%
ROIC(3y)N/A
ROIC(5y)N/A
LFCR Yearly ROA, ROE, ROICLFCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

In the last couple of years the Profit Margin of LFCR has grown nicely.
The Gross Margin of LFCR (34.87%) is worse than 63.16% of its industry peers.
LFCR's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for LFCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.87%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y164.95%
GM growth 3Y3.48%
GM growth 5Y17.57%
LFCR Yearly Profit, Operating, Gross MarginsLFCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60 -80

More info and screens

2

2. Health

2.1 Basic Checks

LFCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LFCR has been increased compared to 1 year ago.
LFCR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for LFCR is higher compared to a year ago.
LFCR Yearly Shares OutstandingLFCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
LFCR Yearly Total Debt VS Total AssetsLFCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of 0.25, we must say that LFCR is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.25, LFCR is doing worse than 71.93% of the companies in the same industry.
A Debt/Equity ratio of 1.99 is on the high side and indicates that LFCR has dependencies on debt financing.
With a Debt to Equity ratio value of 1.99, LFCR is not doing good in the industry: 85.96% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.99
Debt/FCF N/A
Altman-Z 0.25
ROIC/WACCN/A
WACC9.04%
LFCR Yearly LT Debt VS Equity VS FCFLFCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 2.32 indicates that LFCR has no problem at all paying its short term obligations.
LFCR has a Current ratio (2.32) which is comparable to the rest of the industry.
LFCR has a Quick Ratio of 1.21. This is a normal value and indicates that LFCR is financially healthy and should not expect problems in meeting its short term obligations.
LFCR's Quick ratio of 1.21 is on the low side compared to the rest of the industry. LFCR is outperformed by 71.93% of its industry peers.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 1.21
LFCR Yearly Current Assets VS Current LiabilitesLFCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 75.86% over the past year.
Measured over the past years, LFCR shows a very strong growth in Earnings Per Share. The EPS has been growing by 100.00% on average per year.
LFCR shows a strong growth in Revenue. In the last year, the Revenue has grown by 21.40%.
LFCR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -25.47% yearly.
EPS 1Y (TTM)75.86%
EPS 3YN/A
EPS 5Y100%
EPS Q2Q%-164.77%
Revenue 1Y (TTM)21.4%
Revenue growth 3Y-9.23%
Revenue growth 5Y-25.47%
Sales Q2Q%8.01%

3.2 Future

The Earnings Per Share is expected to decrease by -44.81% on average over the next years. This is quite bad
Based on estimates for the next years, LFCR will show a quite strong growth in Revenue. The Revenue will grow by 9.14% on average per year.
EPS Next Y-304.88%
EPS Next 2Y-86.1%
EPS Next 3Y-44.81%
EPS Next 5YN/A
Revenue Next Year2.52%
Revenue Next 2Y5.16%
Revenue Next 3Y7.23%
Revenue Next 5Y9.14%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LFCR Yearly Revenue VS EstimatesLFCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M
LFCR Yearly EPS VS EstimatesLFCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LFCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LFCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LFCR Price Earnings VS Forward Price EarningsLFCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of LFCR is on the same level as its industry peers.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 144.02
LFCR Per share dataLFCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

LFCR's earnings are expected to decrease with -44.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-86.1%
EPS Next 3Y-44.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LFCR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIFECORE BIOMEDICAL INC

NASDAQ:LFCR (2/4/2025, 8:00:02 PM)

After market: 5.94 0 (0%)

5.94

+0.22 (+3.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)01-02 2025-01-02/amc
Earnings (Next)N/A N/A
Inst Owners61.64%
Inst Owner ChangeN/A
Ins Owners1.53%
Ins Owner Change13.82%
Market Cap218.77M
Analysts77.78
Price Target8.67 (45.96%)
Short Float %7.45%
Short Ratio9.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.16%
Min EPS beat(2)-3.31%
Max EPS beat(2)19.64%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.89%
Min Revenue beat(2)4.45%
Max Revenue beat(2)7.32%
Revenue beat(4)3
Avg Revenue beat(4)3.93%
Min Revenue beat(4)-2.14%
Max Revenue beat(4)7.32%
Revenue beat(8)4
Avg Revenue beat(8)2.09%
Revenue beat(12)5
Avg Revenue beat(12)-7.6%
Revenue beat(16)5
Avg Revenue beat(16)-22.98%
PT rev (1m)6.25%
PT rev (3m)21.43%
EPS NQ rev (1m)12.9%
EPS NQ rev (3m)-575%
EPS NY rev (1m)14.72%
EPS NY rev (3m)14.72%
Revenue NQ rev (1m)-2.66%
Revenue NQ rev (3m)-17.29%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.67
P/FCF N/A
P/OCF 619.75
P/B 3.66
P/tB 5.25
EV/EBITDA 144.02
EPS(TTM)-0.59
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)0.01
OCFY0.16%
SpS3.55
BVpS1.62
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.42%
ROE -27.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.87%
FCFM N/A
ROA(3y)-25.28%
ROA(5y)-17.88%
ROE(3y)-129.31%
ROE(5y)-84.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5Y164.95%
GM growth 3Y3.48%
GM growth 5Y17.57%
F-Score6
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 1.99
Debt/FCF N/A
Debt/EBITDA 53.4
Cap/Depr 173.08%
Cap/Sales 11.27%
Interest Coverage N/A
Cash Conversion 15.84%
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 1.21
Altman-Z 0.25
F-Score6
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)173.77%
Cap/Depr(5y)156.52%
Cap/Sales(3y)16.64%
Cap/Sales(5y)16.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.86%
EPS 3YN/A
EPS 5Y100%
EPS Q2Q%-164.77%
EPS Next Y-304.88%
EPS Next 2Y-86.1%
EPS Next 3Y-44.81%
EPS Next 5YN/A
Revenue 1Y (TTM)21.4%
Revenue growth 3Y-9.23%
Revenue growth 5Y-25.47%
Sales Q2Q%8.01%
Revenue Next Year2.52%
Revenue Next 2Y5.16%
Revenue Next 3Y7.23%
Revenue Next 5Y9.14%
EBIT growth 1Y66.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year279.85%
EBIT Next 3Y68.83%
EBIT Next 5YN/A
FCF growth 1Y68.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y101.44%
OCF growth 3YN/A
OCF growth 5YN/A